Targeted therapy for older patients with an oncogene driven non-small cell lung cancer: Recommendations from a SIOG expert group

IF 4.5 2区医学 Q1 ONCOLOGY

Lung Cancer Pub Date : 2025-02-01 DOI:10.1016/j.lungcan.2025.108087

L. Decoster , D.R. Camidge , J.A. Fletcher , A. Addeo , A. Greystoke , K. Kantilal , L.Bigay Game , R. Kanesvaran , F. Gomes

{"title":"Targeted therapy for older patients with an oncogene driven non-small cell lung cancer: Recommendations from a SIOG expert group","authors":"L. Decoster , D.R. Camidge , J.A. Fletcher , A. Addeo , A. Greystoke , K. Kantilal , L.Bigay Game , R. Kanesvaran , F. Gomes","doi":"10.1016/j.lungcan.2025.108087","DOIUrl":null,"url":null,"abstract":"<div><div>Lung cancer is mostly a disease of aging with approximately half of newly diagnosed patients being 70 years or older. Treatment decisions in this population pose unique challenges because of their heterogeneity with regards to daily functioning, cognition, organ function, comorbidities and polypharmacy, their underrepresentation in clinical trials and the impact of treatment on patient-centered outcomes, particularly in frail patients.</div><div>The advent of targeted therapies and immunotherapy has revolutionized the management of advanced non-small cell lung cancer (NSCLC). Molecular profiling has allowed for the identification of actionable genomic alterations and targeted therapies have become standard of care for oncogene-driven NSCLC, significantly improving prognosis and quality of life. However, the data on the efficacy and tolerability of these treatments in older patients remain sparse.</div><div>This review, conducted by the International Society of Geriatric Oncology (SIOG) NSCLC task force, examines the available literature on the use of targeted therapies in patients aged 70 years or older with oncogene-driven NSCLC. The task force’s expert recommendations aim to guide treatment decisions for older patients with oncogene driven NSCLC.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"200 ","pages":"Article 108087"},"PeriodicalIF":4.5000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S016950022500008X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Lung cancer is mostly a disease of aging with approximately half of newly diagnosed patients being 70 years or older. Treatment decisions in this population pose unique challenges because of their heterogeneity with regards to daily functioning, cognition, organ function, comorbidities and polypharmacy, their underrepresentation in clinical trials and the impact of treatment on patient-centered outcomes, particularly in frail patients.

The advent of targeted therapies and immunotherapy has revolutionized the management of advanced non-small cell lung cancer (NSCLC). Molecular profiling has allowed for the identification of actionable genomic alterations and targeted therapies have become standard of care for oncogene-driven NSCLC, significantly improving prognosis and quality of life. However, the data on the efficacy and tolerability of these treatments in older patients remain sparse.

This review, conducted by the International Society of Geriatric Oncology (SIOG) NSCLC task force, examines the available literature on the use of targeted therapies in patients aged 70 years or older with oncogene-driven NSCLC. The task force’s expert recommendations aim to guide treatment decisions for older patients with oncogene driven NSCLC.

查看原文本刊更多论文

老年癌基因驱动的非小细胞肺癌的靶向治疗：SIOG专家组的建议

肺癌主要是一种衰老疾病，大约一半的新诊断患者年龄在70岁或以上。这一人群的治疗决策面临着独特的挑战，因为他们在日常功能、认知、器官功能、合并症和多种药物方面存在异质性，他们在临床试验中的代表性不足，以及治疗对以患者为中心的结果的影响，特别是在虚弱的患者中。靶向治疗和免疫治疗的出现彻底改变了晚期非小细胞肺癌（NSCLC）的治疗。分子谱分析允许识别可操作的基因组改变，靶向治疗已成为癌基因驱动的非小细胞肺癌的标准治疗方法，显著改善预后和生活质量。然而，关于这些治疗在老年患者中的疗效和耐受性的数据仍然很少。本综述由国际老年肿瘤学会（SIOG） NSCLC工作组进行，研究了针对70岁及以上癌基因驱动型NSCLC患者使用靶向治疗的现有文献。工作组的专家建议旨在指导老年癌基因驱动的非小细胞肺癌患者的治疗决策。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Lung Cancer 医学-呼吸系统

CiteScore

9.40

自引率

3.80%

发文量

407

审稿时长

25 days

期刊介绍： Lung Cancer is an international publication covering the clinical, translational and basic science of malignancies of the lung and chest region.Original research articles, early reports, review articles, editorials and correspondence covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, other treatment modalities and outcomes of lung cancer are welcome.